Barclays’s Alder Biopharmaceuticals ALDR Stock Holding History

Barclays’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,600	Closed	-$87K	–	7177
2019 Q3	$87K	Buy	+4,600	New	+$52.6K	﹤0.01%	5584
2017 Q1	–	Sell	-45,000	Closed	-$936K	–	7115
2016 Q4	$936K	Buy	+45,000	New	+$1.17M	﹤0.01%	2812
2016 Q1	–	Sell	-44,000	Closed	-$1.45M	–	6597
2015 Q4	$1.45M	Buy	+44,000	New	+$1.49M	﹤0.01%	2282

Barclays's ALDR Position: Q4 2019 in Review

Barclays sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 197,432 shares — an estimated $3.72M sold.

Barclays first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $3.72M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Barclays reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Barclays sold 197,432 Alder Biopharmaceuticals shares in Q4 2019, an estimated $3.72M.
Barclays first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
Barclays's Alder Biopharmaceuticals position peaked at $3.72M in Q3 2019.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.